A recent study suggests that people who come off new weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass far faster than those who end traditional diet and exercise regimens.
Findings released in a leading health publication demonstrates that while overweight individuals often shed substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping.
"People using such treatments must be aware of the danger of rapid weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment mass in about a year and a half.
Weighing Treatments
The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
Researchers emphasize that individuals who lose weight through lifestyle changes alone usually experience a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Quick Regain
Doctors believe the way of the injections accounts for the accelerated regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to hunger is uncontrolled, making binge eating far more likely."
An Ongoing Condition?
The NHS advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, considering the likelihood of relapse, the therapy is often ongoing.
This view is supported by pharmaceutical companies, who say that the results "emphasize the long-term character of excess weight," akin to managing conditions like high blood pressure.
Patient Experiences
Users who have stopped the medication describe a sudden resurgence of appetite.
"It felt as if a switch activating and I was suddenly ravenous," said one woman.
This challenge is worsened if patients have not developed permanent lifestyle or habit modifications during therapy.
Widespread Interest
Survey data suggest that millions of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is higher among women compared to males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and long-term success relies on combined behavioural changes.
